Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | The role and clinical use of TPO receptor agonists in the treatment of ITP

David Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA, discusses the role and clinical use of thrombopoietin (TPO) receptor agonists in the treatment of immune thrombocytopenia (ITP). Prof. Kuter highlights four currently available agents, three oral (avatrombopag, eltrombopag, and hetrombopag), and one subcutaneous (romiplostim), which have demonstrated high response rates and minimal side effects in patients with newly diagnosed ITP. Accessibility to these agents, however, remains an obstacle to widespread use. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research: Alnylam, Biocryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UCB

Consulting: AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui. Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Platelet Disorder Support Association, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia). Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen

Stock ownership: Rubius